Literature DB >> 17234773

Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions.

Fuqiu He1, Ligeng Li, Dooha Kim, Bixiu Wen, Xuelong Deng, Philip H Gutin, Clifton C Ling, Gloria C Li.   

Abstract

Ku70 is one component of a protein complex, the Ku70/Ku80 heterodimer, which binds to DNA double-strand breaks and activates DNA-dependent protein kinase (DNA-PK), leading to DNA damage repair. Our previous work has confirmed that Ku70 is important for DNA damage repair in that Ku70 deficiency compromises the ability of cells to repair DNA double-strand breaks, increases the radiosensitivity of cells, and enhances radiation-induced apoptosis. Because of the radioresistance of some human cancers, particularly glioblastoma, we examined the use of a radio-gene therapy paradigm to sensitize cells to ionizing radiation. Based on the analysis of the structure-function of Ku70 and the crystal structure of Ku70/Ku80 heterodimer, we designed and identified a candidate dominant negative fragment involving an NH(2)-terminal deletion, and designated it as DNKu70. We generated this mutant construct, stably overexpressed it in Rat-1 cells, and showed that it has a dominant negative effect (i.e., DNKu70 overexpression results in decreased Ku-DNA end-binding activity, and increases radiosensitivity). We then constructed and generated recombinant replication-defective adenovirus, with DNKu70 controlled by the cytomegalovirus promoter, and infected human glioma U-87 MG cells and human colorectal tumor HCT-8 cells. We show that the infected cells significantly express DNKu70 and are greatly radiosensitized under both aerobic and hypoxic conditions. The functional ramification of DNKu70 was further shown in vivo: expression of DNKu70 inhibits radiation-induced DNA-PK catalytic subunit autophosphorylation and prolongs the persistence of gamma-H2AX foci. If radiation-resistant tumor cells could be sensitized by down-regulating the cellular level/activity of Ku/DNA-PK, this approach could be evaluated as an adjuvant to radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17234773     DOI: 10.1158/0008-5472.CAN-06-1860

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  15 in total

1.  Mycobacterium tuberculosis Ku can bind to nuclear DNA damage and sensitize mammalian cells to bleomycin sulfate.

Authors:  Reneau Castore; Cameron Hughes; Austin Debeaux; Jingxin Sun; Cailing Zeng; Shih-Ya Wang; Kelly Tatchell; Runhua Shi; Kyung-Jong Lee; David J Chen; Lynn Harrison
Journal:  Mutagenesis       Date:  2011-08-02       Impact factor: 3.000

2.  Response to multiple radiation doses of fibroblasts over-expressing dominant negative Ku70.

Authors:  Muneyasu Urano; Yunhong Huang; Fuqiu He; Akiko Minami; C Clifton Ling; Gloria C Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

3.  Response to multiple radiation doses of human colorectal carcinoma cells infected with recombinant adenovirus containing dominant-negative Ku70 fragment.

Authors:  Muneyasu Urano; Fuqiu He; Akiko Minami; C Clifton Ling; Gloria C Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-01       Impact factor: 7.038

4.  Non-invasive molecular and functional imaging of cytosine deaminase and uracil phosphoribosyltransferase fused with red fluorescence protein.

Authors:  Ligang Xing; Xuelong Deng; Khushali Kotedia; Ellen Ackerstaff; Vladimir Ponomarev; C Clifton Ling; Jason A Koutcher; Gloria C Li
Journal:  Acta Oncol       Date:  2008       Impact factor: 4.089

5.  The radiosensitizing effect of Ku70/80 knockdown in MCF10A cells irradiated with X-rays and p(66)+Be(40) neutrons.

Authors:  Veerle Vandersickel; Monica Mancini; Jacobus Slabbert; Emanuela Marras; Hubert Thierens; Gianpaolo Perletti; Anne Vral
Journal:  Radiat Oncol       Date:  2010-04-27       Impact factor: 3.481

6.  Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer.

Authors:  Young Eun Choi; Khyati Meghani; Marie-Eve Brault; Lucas Leclerc; Yizhou J He; Tovah A Day; Kevin M Elias; Ronny Drapkin; David M Weinstock; Fanny Dao; Karin K Shih; Ursula Matulonis; Douglas A Levine; Panagiotis A Konstantinopoulos; Dipanjan Chowdhury
Journal:  Cell Rep       Date:  2016-01-07       Impact factor: 9.423

7.  Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers.

Authors:  Fuqiu He; Xuelong Deng; Bixiu Wen; Yueping Liu; Xiaorong Sun; Ligang Xing; Akiko Minami; Yunhong Huang; Qing Chen; Pat B Zanzonico; C Clifton Ling; Gloria C Li
Journal:  Cancer Res       Date:  2008-10-15       Impact factor: 12.701

8.  Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells.

Authors:  Susan C Short; Silvia Giampieri; Mulugeta Worku; Marisa Alcaide-German; George Sioftanos; Sara Bourne; Ka Ian Lio; Maya Shaked-Rabi; Christine Martindale
Journal:  Neuro Oncol       Date:  2011-03-01       Impact factor: 12.300

9.  Inhibition of human positive cofactor 4 radiosensitizes human esophageal squmaous cell carcinoma cells by suppressing XLF-mediated nonhomologous end joining.

Authors:  D Qian; B Zhang; X-L Zeng; J M Le Blanc; Y-H Guo; C Xue; C Jiang; H-H Wang; T-S Zhao; M-B Meng; L-J Zhao; J-H Hao; P Wang; D Xie; B Lu; Z-Y Yuan
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

10.  DNAPK Inhibition Preferentially Compromises the Repair of Radiation-induced DNA Double-strand Breaks in Chronically Hypoxic Tumor Cells in Xenograft Models.

Authors:  Yanyan Jiang; Elaine Willmore; Stephen R Wedge; Anderson J Ryan
Journal:  Mol Cancer Ther       Date:  2021-06-22       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.